It’s good to see some progress on treating the awful diseases we call mesothelioma. It’s also good to see that progress followed and mentioned by others on the defense side of the litigation. On both topics, see this April 3, 2015 post from Ed Casmere and Emily Gesmundo at the Product Liability & Mass Torts Blog from Schiff Hardin. The post is about a new orphan drug, CRS-207, made by Aduro Biotech, Inc.
top of page
The Intersection Among Torts, Science, Corporate Law, Insurance & Bankruptcy
GlobalTort
Search
Recent Posts
See AllIssues arising from criminal prosecutions of former managers at an asbestos-cement plant (Everite) are up on appeal, as described in a...
Some "toxins" are long-lived, and so decisions made decades ago continue to ripple through current events. A "now in the news" example is...
The Isle of Jersey will be making lump sum mesothelioma payments as a result of citizen requests through an “e-petition,” as described in...
bottom of page
Comentarios